VARIANTS OF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR HAVING ALTERED PHARMACOLOGICAL PROPERTIES, AND RELATED ASPECTS THEREOF

摘要

Disclosed are vascular endothelial cell growth factor variants having a C-terminus heparin binding domain modification, as well as all associated recombinant technology including DNA encoding such variants, transformed host cells and methods for preparing such variants. These variants are described as having altered binding characteristics such that the variant has a reduced clearance rate compared with native material.